Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
IDENIX PHARMACEUTICALS INC (IDIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/05/2014 8-K Form 8-K - Current report
07/31/2014 8-K Quarterly results
Docs: "IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS CAMBRIDGE, Mass., July 31, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter ended June 30, 2014. Second Quarter and Six Months 2014 Financial Results For the second quarter ended June 30, 2014, Idenix reported total revenues of $ million, compared to total revenues of $0.1 million in the second quarter of 2013. The Company reported a net loss of $64.5 million, or $0.43 per basic and diluted share, for the second quarter ended June 30, 2014, compared to a net loss of $28.9 million, or $0.22 per basic and diluted share, for the second qu..."
06/17/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Letter, by and between Idenix Pharmaceuticals, Inc. and Paul Fanning"
06/09/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among the Company, Merck & Co., Inc. and Imperial Blue Corporation",
"Support Agreement, by and among Merck & Co., Inc., Imperial Blue Corporation and The Baupost Group, L.L.C",
"Merck to Acquire Idenix Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C"
06/06/2014 8-K Submission of Matters to a Vote of Security Holders
05/01/2014 8-K Quarterly results
Docs: "IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS AND HCV PIPELINE REVIEW CAMBRIDGE, Mass., May 1, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014. HCV Pipeline Review • In April 2014, Idenix reported positive seven-day proof-of-concept data from a phase I/II clinical trial for IDX21437, the Company's lead uridine-based nucleotide prodrug candidate. The trial demonstrated that IDX21437 was well tolerated and exhibited potent pan-genotypic activity with mean maximal viral load reductions of 4.2 - 4.3 log 10 IU/mL for treatment-naïve genotype 1, 2 and 3 HCV-infected patients ..."
04/07/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C"
04/03/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/24/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case CAMBRIDGE, Mass., March 24, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus and other flaviviridae infections. In September 2012, Gilead Sciences Europe Ltd., a subsidiary of Gilead Sciences, Inc. , filed a lawsuit in the Court claiming that Idenix's Norwegian patent NO 330 755 is i..."
03/14/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS FILES PATENT INFRINGEMENT LAWSUITS AGAINST GILEAD SCIENCES IN EUROPE"
02/27/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2013 FINANCIAL RESULTS"
02/14/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/29/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS ANNOUNCES DECISION BY THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD IN THE FIRST PATENT INTERFERNCE CAMBRIDGE, Mass., January 29, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office Patent Trial and Appeal Board issued a decision in the first patent interference proceeding concerning one of the Company's patent applications and an issued patent owned by Gilead Pharmasset LLC that covers certain 2'-methyl- 2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus . The USPTO determined that Idenix is not entitled to priority of invention and judg..."
01/28/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Subscription Agreement",
"Letter Agreement",
"IDENIX TO RAISE $106.7 MILLION THROUGH REGISTERED DIRECT OFFERING"
01/13/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Idenix Pharmaceuticals Reports Sustained Virologic Response Rate for Phase II All-Oral Combination Study of Samatasvir , a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir CAMBRIDGE, Mass., Jan. 13, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from the Company's ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral HCV combination regimen of samatasvir , Idenix's once-daily pan-genotypic NS5A inhibitor, and simeprevir , a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, plus ribavirin. The combination regimen was well-tolerated in the study. In the treatment-na&i..."
01/06/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Letter, by and between Idenix Pharmaceuticals, Inc. and Jacques Dumas, Ph.D"
12/09/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS ANNOUNCES DECLARATION OF SENIOR PARTY IN A SECOND PATENT INTERFERENCE BY THE USPTO CAMBRIDGE, Mass., December 9, 2013 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office declared a patent interference between Idenix's U.S. Patent 7,608,600 and Gilead Sciences, Inc.'s U.S. Patent Application 11/854,218, both related to the use of certain 2'-methyl, 2'-fluoro nucleoside compounds to treat hepatitis C virus infections. A patent interference is an administrative proceeding conducted by the USPTO in order to determine which party is entitled to a patent when two or more parties claim patent right..."
12/02/2013 8-K Form 8-K - Current report
10/30/2013 8-K Quarterly results
Docs: "IDENIX PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTH 2013 FINANCIAL RESULTS AND PROVIDES HCV PIPELINE UPDATE"
09/10/2013 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
08/07/2013 8-K Quarterly results
Docs: "IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2013 FINANCIAL RESULTS"
06/10/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "IDENIX PHARMACEUTICALS APPOINTS CHARLES ROWLAND TO ITS BOARD OF DIRECTORS"
06/10/2013 8-K Submission of Matters to a Vote of Security Holders
03/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS ANNOUNCES DECISION BY THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD IN THE FIRST PHASE OF THE INTERFERENCE"
02/26/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2012 FINANCIAL RESULTS"
12/26/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/01/2012 8-K Quarterly results
Docs: "IDENIX PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTH 2012 FINANCIAL RESULTS AND HCV PROGRAM UPDATE"
09/28/2012 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
09/20/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "General Investor Presentation Slides"
08/27/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "IDENIX PROVIDES UPDATE ON IDX19368 DEVELOPMENT PROGRAM - IDX19368, for which Idenix has submitted an IND application, has been placed on clinical hold by FDA -"
07/31/2012 8-K Form 8-K - Current report
07/31/2012 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Second Amended and Restated Stock Purchase Agreement, between the Registrant, Novartis Pharma AG and certain other stockholders defined therein",
"Slide Outlining Changes to Collaboration between the Registrant and Novartis Pharma AG"
06/20/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719 — In an interim analysis from an ongoing phase IIb clinical trial of IDX184, an HCV nucleotide inhibitor, 89% of patients who completed an additional 12 weeks of pegylated interferon plus ribavirin treatment achieved SVR4; 100% in 100 mg arm and 80% in 50 mg arm — — IDX719, an HCV NS5A inhibitor, achieves potent pan-genotypic activity in three-day proof-of-concept clinical trial"
06/08/2012 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy